上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
RX-3117 (Synonyms: TV-1360; fluorocyclopentenylcytosine) 纯度: 98.38%
RX-3117(TV-1360; Fluorocyclopentenylcytosine)是新型胞苷类似物,在多种癌细胞株中证明有抗癌活性,包括吉西他滨耐受细胞株。

RX-3117 Chemical Structure
CAS No. : 865838-26-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥3254 | In-stock | |
2 mg | ¥2300 | In-stock | |
5 mg | ¥3500 | In-stock | |
10 mg | ¥5000 | In-stock | |
50 mg | 询价 |
* Please select Quantity before adding items.
RX-3117 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
- Cell Cycle/DNA Damage Compound Library
- Anti-Cancer Compound Library
- Clinical Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Reprogramming Compound Library
- Anti-COVID-19 Compound Library
- Orally Active Compound Library
- Anti-Lung Cancer Compound Library
- Anti-Blood Cancer Compound Library
- Anti-Cancer Metabolism Compound Library
生物活性 |
RX-3117(TV-1360; Fluorocyclopentenylcytosine) is novel a cytidine analog; shows anticancer activity in several cancer cell lines, including gemcitabine-resistant variants. IC50 value: 0.4- >30 nM (15 cancer cell lines) [1] Target: cytidine analog in vitro: RX-3117 showed a different sensitivity profile compared to cyclopentenyl-cytosine (CPEC) and azacytidine, substrates for uridine-cytidine-kinase (UCK).RX-3117 was a very poor substrate for cytidine deaminase (66,000-fold less than gemcitabine). In sensitive U937 cells 1 μM RX-3117 resulted in 90% inhibition of RNA synthesis but 100 μM RX-3117 was required in A2780 and CCRF-CEM cells. RX-3117 at IC50 values did not affect the integrity of RNA [1]. in vivo: Orally-administered RX-3117 was examined in 9 different human tumor xenograft models (colon, non-small cell lung, small cell lung, pancreatic, renal and cervical), grown subcutaneously in athymic nude mice. In the Colo 205, H460, H69 and CaSki models, gemcitabine treatment resulted in 28%, 30%, 25% and 0% tumor growth inhibition (TGI), respectively, whereas oral treatment with RX-3117 induced 100%, 78%, 62% and 66% TGI, respectively [2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical Trial |
|
||||||||||||||||
分子量 |
257.22 |
||||||||||||||||
Formula |
C10H12FN3O4 |
||||||||||||||||
CAS 号 |
865838-26-2 |
||||||||||||||||
中文名称 |
氟环戊烯基胞嘧啶 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 50 mg/mL (194.39 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务